{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:13:21Z","timestamp":1776111201744,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["412642"],"award-info":[{"award-number":["412642"]}]},{"name":"NIH","award":["412642"],"award-info":[{"award-number":["412642"]}]},{"name":"NIH","award":["412642"],"award-info":[{"award-number":["412642"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29583-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T21:22:28Z","timestamp":1766092948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci"],"prefix":"10.1038","volume":"16","author":[{"given":"Somaia M.","family":"Abdelmegeed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"29583_CR1","doi-asserted-by":"publisher","unstructured":"Guzman Prieto, A. M. et al. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? Front. Microbiol. 7 https:\/\/doi.org\/10.3389\/fmicb.2016.00788 (2016).","DOI":"10.3389\/fmicb.2016.00788"},{"key":"29583_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/0255-0857.174099","volume":"34","author":"A Tripathi","year":"2016","unstructured":"Tripathi, A., Shukla, S. K., Singh, A. & Prasad, K. N. Prevalence, outcome and risk factor associated with vancomycin-resistant Enterococcus faecalis and Enterococcus faecium at a tertiary care hospital in Northern India. Ind. J. Med. Microbiol. 34, 38\u201345. https:\/\/doi.org\/10.4103\/0255-0857.174099 (2016).","journal-title":"Ind. J. Med. Microbiol."},{"key":"29583_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/antibiotics14050522","volume":"14","author":"DE Radford-Smith","year":"2025","unstructured":"Radford-Smith, D. E., Anthony, D. C. & Vancomycin-Resistant, E. Faecium: addressing global and clinical challenges. Antibiotics 14, 522 (2025).","journal-title":"Antibiotics"},{"key":"29583_CR4","doi-asserted-by":"publisher","unstructured":"Rotondo, C. et al. Surveillance and characterization of Vancomycin-Resistant and Vancomycin-Variable enterococci in a hospital setting. Antibiot. (Basel). 14. https:\/\/doi.org\/10.3390\/antibiotics14080795 (2025).","DOI":"10.3390\/antibiotics14080795"},{"key":"29583_CR5","doi-asserted-by":"publisher","first-page":"18597","DOI":"10.1021\/acs.jmedchem.5c01584","volume":"68","author":"KJ Holly","year":"2025","unstructured":"Holly, K. J. et al. Hit-to-Lead optimization of Acetazolamide-Based bacterial carbonic anhydrase inhibitors with efficacy in vivo for treatment of Vancomycin-Resistant enterococci septicemia. J. Med. Chem. 68, 18597\u201318624. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01584 (2025).","journal-title":"J. Med. Chem."},{"key":"29583_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1089\/mdr.2017.0147","volume":"24","author":"MO Ahmed","year":"2017","unstructured":"Ahmed, M. O., Baptiste, K. E. & Vancomycin-Resistant Enterococci A review of antimicrobial resistance mechanisms and perspectives of human and animal health. Microb. Drug Resist. 24, 590\u2013606. https:\/\/doi.org\/10.1089\/mdr.2017.0147 (2017).","journal-title":"Microb. Drug Resist."},{"key":"29583_CR7","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1021\/acs.jmedchem.0c00734","volume":"63","author":"J Kaur","year":"2020","unstructured":"Kaur, J. et al. Optimization of Acetazolamide-Based scaffold as potent inhibitors of Vancomycin-Resistant Enterococcus. J. Med. Chem. 63, 9540\u20139562. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00734 (2020).","journal-title":"J. Med. Chem."},{"key":"29583_CR8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/14756366.2022.2092729","volume":"37","author":"W An","year":"2022","unstructured":"An, W. et al. Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrases. J. Enzyme Inhib. Med. Chem. 37, 1838\u20131844. https:\/\/doi.org\/10.1080\/14756366.2022.2092729 (2022).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"29583_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet. Infect. Dis. 18, 318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3 (2018).","journal-title":"Lancet. Infect. Dis"},{"key":"29583_CR10","unstructured":"Organization, W. H. WHO bacterial priority pathogens list, : Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Report No. 978-92-4-009346-1, (World Health Organization, 2024). (2024)."},{"key":"29583_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/acsmedchemlett.3c00032","volume":"14","author":"NS Abutaleb","year":"2023","unstructured":"Abutaleb, N. S., Shrinidhi, A., Bandara, A. B., Seleem, M. N. & Flaherty, D. P. Evaluation of 1,3,4-Thiadiazole carbonic anhydrase inhibitors for gut decolonization of Vancomycin-Resistant enterococci. ACS Med. Chem. Lett. 14, 487\u2013492. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00032 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"29583_CR12","doi-asserted-by":"publisher","unstructured":"Britt, N. S., Potter, E. M., Patel, N. & Steed, M. E. Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for Vancomycin-Resistant Enterococcus faecium bacteremia. Antimicrob. Agents Chemother. 61 https:\/\/doi.org\/10.1128\/aac.02216-16 (2017).","DOI":"10.1128\/aac.02216-16"},{"key":"29583_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fphar.2016.00325","volume":"7","author":"OK Abou Hassan","year":"2016","unstructured":"Abou Hassan, O. K. et al. Linezolid toxicity and mitochondrial susceptibility: A novel neurological complication in a Lebanese patient. Front. Pharmacol. 7, 325. https:\/\/doi.org\/10.3389\/fphar.2016.00325 (2016).","journal-title":"Front. Pharmacol."},{"key":"29583_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/cir.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour, L. M. et al. Infective endocarditis in adults: Diagnosis, antimicrobial Therapy, and management of complications: A scientific statement for healthcare professionals from the American heart association. Circulation 132, 1435\u20131486. https:\/\/doi.org\/10.1161\/cir.0000000000000296 (2015).","journal-title":"Circulation"},{"key":"29583_CR15","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.jmedchem.6b01780","volume":"60","author":"H Mohammad","year":"2017","unstructured":"Mohammad, H. et al. Phenylthiazole antibacterial agents targeting cell wall synthesis exhibit potent activity in vitro and in vivo against Vancomycin-Resistant enterococci. J. Med. Chem. 60, 2425\u20132438. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01780 (2017).","journal-title":"J. Med. Chem."},{"key":"29583_CR16","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1128\/jcm.02412-05","volume":"44","author":"SM Donabedian","year":"2006","unstructured":"Donabedian, S. M. et al. Quinupristin-Dalfopristin resistance in Enterococcus faecium isolates from Humans, farm Animals, and grocery store meat in the united States. J. Clin. Microbiol. 44, 3361\u20133365. https:\/\/doi.org\/10.1128\/jcm.02412-05 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"29583_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","volume":"357","author":"RD Gonzales","year":"2001","unstructured":"Gonzales, R. D. et al. Infections due to vancomycin-resistant\u2009<\u2009em\u2009>\u2009Enterococcus faecium resistant to linezolid. Lancet 357, 1179. https:\/\/doi.org\/10.1016\/S0140-6736(00)04376-2 (2001).","journal-title":"Lancet"},{"key":"29583_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1086\/432121","volume":"41","author":"LS Munoz-Price","year":"2005","unstructured":"Munoz-Price, L. S., Lolans, K. & Quinn, J. P. Emergence of resistance to daptomycin during treatment of Vancomycin-Resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41, 565\u2013566. https:\/\/doi.org\/10.1086\/432121 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"29583_CR19","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ijantimicag.2019.10.009","volume":"55","author":"NS Abutaleb","year":"2020","unstructured":"Abutaleb, N. S. & Seleem, M. N. Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies. Int. J. Antimicrob. Agents. 55, 105828. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.009 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"29583_CR20","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2174\/1381612823666170209154745","volume":"23","author":"W Younis","year":"2017","unstructured":"Younis, W., AbdelKhalek, A., Mayhoub, A. S. & Seleem, M. N. In vitro screening of an FDA-Approved library against ESKAPE pathogens. Curr. Pharm. Des. 23, 2147\u20132157. https:\/\/doi.org\/10.2174\/1381612823666170209154745 (2017).","journal-title":"Curr. Pharm. Des."},{"key":"29583_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"29583_CR22","doi-asserted-by":"publisher","first-page":"e0199710","DOI":"10.1371\/journal.pone.0199710","volume":"13","author":"A AbdelKhalek","year":"2018","unstructured":"AbdelKhalek, A., Abutaleb, N. S., Mohammad, H. & Seleem, M. N. Repurposing Ebselen for decolonization of vancomycin-resistant enterococci (VRE). PLoS One. 13, e0199710. https:\/\/doi.org\/10.1371\/journal.pone.0199710 (2018).","journal-title":"PLoS One"},{"key":"29583_CR23","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1038\/s41598-018-26674-0","volume":"8","author":"A AbdelKhalek","year":"2018","unstructured":"AbdelKhalek, A., Abutaleb, N. S., Elmagarmid, K. A. & Seleem, M. N. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci. Sci. Rep. 8, 8353. https:\/\/doi.org\/10.1038\/s41598-018-26674-0 (2018).","journal-title":"Sci. Rep."},{"key":"29583_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ijantimicag.2018.02.003","volume":"51","author":"H Mohammad","year":"2018","unstructured":"Mohammad, H., AbdelKhalek, A., Abutaleb, N. S. & Seleem, M. N. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. Int. J. Antimicrob. Agents. 51, 897\u2013904. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.02.003 (2018).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"29583_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrd4675","volume":"14","author":"D Brown","year":"2015","unstructured":"Brown, D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat. Rev. Drug Discovery. 14, 821\u2013832. https:\/\/doi.org\/10.1038\/nrd4675 (2015).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"29583_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s10123-024-00506-w","volume":"27","author":"MM Abdelmassih","year":"2024","unstructured":"Abdelmassih, M. M., Ismail, M. M., Kashef, M. T. & Essam, T. Repurposing fusidic acid as an antimicrobial against enterococci with a low probability of resistance development. Int. Microbiol. 27, 1807\u20131819. https:\/\/doi.org\/10.1007\/s10123-024-00506-w (2024).","journal-title":"Int. Microbiol."},{"key":"29583_CR27","doi-asserted-by":"publisher","first-page":"e0141222","DOI":"10.1128\/spectrum.01412-22","volume":"10","author":"S Gargvanshi","year":"2022","unstructured":"Gargvanshi, S. & Gutheil, W. G. Library screening for synergistic combinations of FDA-Approved drugs and metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium. Microbiol. Spectr. 10, e0141222. https:\/\/doi.org\/10.1128\/spectrum.01412-22 (2022).","journal-title":"Microbiol. Spectr."},{"key":"29583_CR28","doi-asserted-by":"publisher","first-page":"e11059","DOI":"10.7717\/peerj.11059","volume":"9","author":"NS Abutaleb","year":"2021","unstructured":"Abutaleb, N. S., Elhassanny, A. E. M., Flaherty, D. P. & Seleem, M. N. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 9, e11059. https:\/\/doi.org\/10.7717\/peerj.11059 (2021).","journal-title":"PeerJ"},{"key":"29583_CR29","doi-asserted-by":"publisher","unstructured":"Abdelmegeed, S. M., Mohamed, M. F. & Seleem, M. N. Repurposing Antibacterial Drugs and Clinical Molecules to Combat Vancomycin-Resistant Enterococci (VRE). bioRxiv, 2025.2003.2027.645859, (2025). https:\/\/doi.org\/10.1101\/2025.03.27.645859","DOI":"10.1101\/2025.03.27.645859"},{"key":"29583_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bbagen.2017.01.029","volume":"1861","author":"MF Mohamed","year":"2017","unstructured":"Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J. & Seleem, M. N. Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a Kanamycin peptide conjugate. Biochim. Biophys. Acta Gen. Subj. 1861, 848\u2013859. https:\/\/doi.org\/10.1016\/j.bbagen.2017.01.029 (2017).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"29583_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2174\/1389201017666160808160513","volume":"17","author":"A Adan","year":"2016","unstructured":"Adan, A., Kiraz, Y. & Baran, Y. Cell proliferation and cytotoxicity assays. Curr. Pharm. Biotechnol. 17, 1213\u20131221. https:\/\/doi.org\/10.2174\/1389201017666160808160513 (2016).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"29583_CR32","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1038\/s41598-017-07440-0","volume":"7","author":"MF Mohamed","year":"2017","unstructured":"Mohamed, M. F., Brezden, A., Mohammad, H., Chmielewski, J. & Seleem, M. N. A short D-enantiomeric antimicrobial peptide with potent Immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and acinetobacter baumannii. Sci. Rep. 7, 6953. https:\/\/doi.org\/10.1038\/s41598-017-07440-0 (2017).","journal-title":"Sci. Rep."},{"key":"29583_CR33","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1128\/aac.02578-14","volume":"58","author":"MF Mohamed","year":"2014","unstructured":"Mohamed, M. F., Hamed, M. I., Panitch, A. & Seleem, M. N. Targeting Methicillin-Resistant Staphylococcus aureus with short Salt-Resistant synthetic peptides. Antimicrob. Agents Chemother. 58, 4113\u20134122. https:\/\/doi.org\/10.1128\/aac.02578-14 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR34","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1128\/aac.01285-10","volume":"55","author":"J Farrell David","year":"2011","unstructured":"Farrell David, J., Robbins, M., Rhys-Williams, W. & Love William, G. Investigation of the potential for mutational resistance to XF-73, Retapamulin, Mupirocin, fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus isolates during a 55-Passage study. Antimicrob. Agents Chemother. 55, 1177\u20131181. https:\/\/doi.org\/10.1128\/aac.01285-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR35","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1073\/pnas.0604055103","volume":"103","author":"TI Moy","year":"2006","unstructured":"Moy, T. I. et al. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. 103, 10414\u201310419. https:\/\/doi.org\/10.1073\/pnas.0604055103 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"29583_CR36","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/nprot.2008.193","volume":"3","author":"E Tampakakis","year":"2008","unstructured":"Tampakakis, E., Okoli, I. & Mylonakis, E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat. Protoc. 3, 1925\u20131931. https:\/\/doi.org\/10.1038\/nprot.2008.193 (2008).","journal-title":"Nat. Protoc."},{"key":"29583_CR37","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1128\/iai.06350-11","volume":"80","author":"Y Kim","year":"2012","unstructured":"Kim, Y. & Mylonakis, E. Caenorhabditis elegans immune conditioning with the probiotic bacterium Lactobacillus acidophilus strain NCFM enhances gram-positive immune responses. Infect. Immun. 80, 2500\u20132508. https:\/\/doi.org\/10.1128\/iai.06350-11 (2012).","journal-title":"Infect. Immun."},{"key":"29583_CR38","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1073\/pnas.191378698","volume":"98","author":"DA Garsin","year":"2001","unstructured":"Garsin, D. A. et al. A simple model host for identifying Gram-positive virulence factors. Proc. Natl. Acad. Sci. U S A. 98, 10892\u201310897. https:\/\/doi.org\/10.1073\/pnas.191378698 (2001).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"29583_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/lam.13664","volume":"75","author":"DA Collins","year":"2022","unstructured":"Collins, D. A. & Riley, T. V. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting clostridium (Clostridioides) difficile. Lett. Appl. Microbiol. 75, 526\u2013536. https:\/\/doi.org\/10.1111\/lam.13664 (2022).","journal-title":"Lett. Appl. Microbiol."},{"key":"29583_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/jac\/dkp041","volume":"63","author":"IA Critchley","year":"2009","unstructured":"Critchley, I. A. et al. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat clostridium difficile infections. J. Antimicrob. Chemother. 63, 954\u2013963. https:\/\/doi.org\/10.1093\/jac\/dkp041 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"29583_CR41","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1128\/aac.49.10.4253-4262.2005","volume":"49","author":"UA Ochsner","year":"2005","unstructured":"Ochsner, U. A. et al. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob. Agents Chemother. 49, 4253\u20134262. https:\/\/doi.org\/10.1128\/aac.49.10.4253-4262.2005 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR42","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1128\/aac.01136-13","volume":"57","author":"JC Goldstein Ellie","year":"2013","unstructured":"Goldstein Ellie, J. C., Diane, C., Tyrrell Kerin, M., Merriam, C. V. & L. & Comparative in vitro activities of SMT19969, a new antimicrobial Agent, against clostridium difficile and 350 Gram-Positive and Gram-Negative aerobic and anaerobic intestinal flora isolates. Antimicrob. Agents Chemother. 57, 4872\u20134876. https:\/\/doi.org\/10.1128\/aac.01136-13 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR43","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1086\/381972","volume":"38","author":"GA Pankey","year":"2004","unstructured":"Pankey, G. A. & Sabath, L. D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-Positive bacterial infections. Clin. Infect. Dis. 38, 864\u2013870. https:\/\/doi.org\/10.1086\/381972 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"29583_CR44","doi-asserted-by":"publisher","unstructured":"Nayak, S. U. et al. Tolerability, systemic Exposure, and metabolism of CRS3123, a Methionyl-tRNA synthetase inhibitor developed for treatment of clostridium difficile, in a phase 1 study. Antimicrob. Agents Chemother. 61 https:\/\/doi.org\/10.1128\/aac.02760-16 (2017). Safety.","DOI":"10.1128\/aac.02760-16"},{"key":"29583_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijantimicag.2016.04.026","volume":"48","author":"RJ Vickers","year":"2016","unstructured":"Vickers, R. J. et al. Ridinilazole: a novel therapy for clostridium difficile infection. Int. J. Antimicrob. Agents. 48, 137\u2013143. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.026 (2016).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"29583_CR46","doi-asserted-by":"publisher","unstructured":"Nayak, S. U. et al. Safety. Tolerability, systemic Exposure, and metabolism of CRS3123, a Methionyl-tRNA synthetase inhibitor developed for treatment of clostridium difficile, in a phase 1 study. Antimicrob. Agents Chemother. 61 https:\/\/doi.org\/10.1128\/aac.02760-16 (2017).","DOI":"10.1128\/aac.02760-16"},{"key":"29583_CR47","doi-asserted-by":"publisher","first-page":"e01563","DOI":"10.1128\/aac.01563-22","volume":"67","author":"CS Mason","year":"2023","unstructured":"Mason, C. S. et al. The novel DNA binding mechanism of Ridinilazole, a Precision\u2009<\u2009i\u2009>\u2009Clostridiodes difficile Antibiotic. Antimicrob. Agents Chemother. 67, e01563\u2013e01522. https:\/\/doi.org\/10.1128\/aac.01563-22 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR48","doi-asserted-by":"publisher","first-page":"16156","DOI":"10.1038\/s41598-023-43300-w","volume":"13","author":"SG Downes","year":"2023","unstructured":"Downes, S. G. et al. Gliotoxin-mediated bacterial growth Inhibition is caused by specific metal ion depletion. Sci. Rep. 13, 16156. https:\/\/doi.org\/10.1038\/s41598-023-43300-w (2023).","journal-title":"Sci. Rep."},{"key":"29583_CR49","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3389\/fmicb.2018.02541","volume":"9","author":"NS Torres","year":"2018","unstructured":"Torres, N. S. et al. Antimicrobial and antibiofilm activity of synergistic combinations of a commercially available small compound library with colistin against Pseudomonas aeruginosa. Front. Microbiol. 9, 2541. https:\/\/doi.org\/10.3389\/fmicb.2018.02541 (2018).","journal-title":"Front. Microbiol."},{"key":"29583_CR50","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1021\/acsinfecdis.9b00378","volume":"6","author":"M Saedtler","year":"2020","unstructured":"Saedtler, M. et al. Antibacterial anacardic acid derivatives. ACS Infect. Dis. 6, 1674\u20131685. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00378 (2020).","journal-title":"ACS Infect. Dis."},{"key":"29583_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12903-023-02972-6","volume":"23","author":"S Lv","year":"2023","unstructured":"Lv, S., Fan, W. & Fan, B. Enhanced in vitro antibacterial effect against Enterococcus faecalis by using both low-dose cetylpyridinium chloride and silver ions. BMC Oral Health. 23, 299. https:\/\/doi.org\/10.1186\/s12903-023-02972-6 (2023).","journal-title":"BMC Oral Health"},{"key":"29583_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.phymed.2003.09.012","volume":"12","author":"Y Sakagami","year":"2005","unstructured":"Sakagami, Y., Iinuma, M., Piyasena, K. G. & Dharmaratne, H. R. Antibacterial activity of alpha-mangostin against Vancomycin resistant enterococci (VRE) and synergism with antibiotics. Phytomedicine 12, 203\u2013208. https:\/\/doi.org\/10.1016\/j.phymed.2003.09.012 (2005).","journal-title":"Phytomedicine"},{"key":"29583_CR53","doi-asserted-by":"publisher","unstructured":"Abutaleb, N. S., Elkashif, A., Flaherty, D. P. & Seleem, M. N. In vivo antibacterial activity of Acetazolamide. Antimicrob. Agents Chemother. 65 https:\/\/doi.org\/10.1128\/AAC.01715-20 (2021).","DOI":"10.1128\/AAC.01715-20"},{"key":"29583_CR54","doi-asserted-by":"publisher","first-page":"116077","DOI":"10.1016\/j.ejmech.2023.116077","volume":"266","author":"D Nawrot","year":"2024","unstructured":"Nawrot, D., Ambro\u017ckiewicz-Mosler, W., Dole\u017eal, M. & Bouz, G. Antistaphylococcal discovery pipeline; where are we now? Eur. J. Med. Chem. 266, 116077. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116077 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"29583_CR55","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/aac.37.12.2736","volume":"37","author":"P French","year":"1993","unstructured":"French, P., Venuti, E. & Fraimow, H. S. In vitro activity of Novobiocin against multiresistant strains of Enterococcus faecium. Antimicrob. Agents Chemother. 37, 2736\u20132739. https:\/\/doi.org\/10.1128\/aac.37.12.2736 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ja.2012.77","volume":"65","author":"NM Haste","year":"2012","unstructured":"Haste, N. M. et al. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J. Antibiot. (Tokyo). 65, 593\u2013598. https:\/\/doi.org\/10.1038\/ja.2012.77 (2012).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"29583_CR57","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1128\/aac.00212-10","volume":"54","author":"AB Reid","year":"2010","unstructured":"Reid, A. B., Daffy, J. R., Stanley, P. & Buising, K. L. Use of Pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob. Agents Chemother. 54, 3949\u20133952. https:\/\/doi.org\/10.1128\/aac.00212-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR58","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/aac.00533-12","volume":"56","author":"HY Tsai","year":"2012","unstructured":"Tsai, H. Y. et al. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob. Agents Chemother. 56, 3402\u20133405. https:\/\/doi.org\/10.1128\/aac.00533-12 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR59","doi-asserted-by":"publisher","unstructured":"Nurmala, A. et al. Monomyristin and monopalmitin derivatives: synthesis and evaluation as potential antibacterial and antifungal agents. Molecules 23 https:\/\/doi.org\/10.3390\/molecules23123141 (2018).","DOI":"10.3390\/molecules23123141"},{"key":"29583_CR60","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ijantimicag.2019.10.009","volume":"55","author":"NS Abutaleb","year":"2020","unstructured":"Abutaleb, N. S. & Seleem, M. N. Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies. Int. J. Antimicrob. Agents. 55, 105828. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.009 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"29583_CR61","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1128\/aac.01923-15","volume":"60","author":"P Seiler","year":"2016","unstructured":"Seiler, P. et al. Cadazolid does not promote intestinal colonization of Vancomycin-Resistant enterococci in mice. Antimicrob. Agents Chemother. 60, 628\u2013631. https:\/\/doi.org\/10.1128\/aac.01923-15 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR62","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.2147\/idr.S331345","volume":"14","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Comparison of Anti-Microbic and Anti-Biofilm activity among tedizolid and Radezolid against Linezolid-Resistant Enterococcus faecalis isolates. Infect. Drug Resist. 14, 4619\u20134627. https:\/\/doi.org\/10.2147\/idr.S331345 (2021).","journal-title":"Infect. Drug Resist."},{"key":"29583_CR63","doi-asserted-by":"publisher","unstructured":"Paukner, S., Riedl, R. & Pleuromutilins Potent drugs for resistant Bugs-Mode of action and resistance. Cold Spring Harb Perspect. Med. 7 https:\/\/doi.org\/10.1101\/cshperspect.a027110 (2017).","DOI":"10.1101\/cshperspect.a027110"},{"key":"29583_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.20411\/pai.v2i2.200","volume":"2","author":"DL Popkin","year":"2017","unstructured":"Popkin, D. L. et al. Cetylpyridinium chloride (CPC) exhibits Potent, rapid activity against influenza viruses in vitro and in vivo. Pathog Immun. 2, 252\u2013269. https:\/\/doi.org\/10.20411\/pai.v2i2.200 (2017).","journal-title":"Pathog Immun."},{"key":"29583_CR65","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/jac\/dkae331","volume":"79","author":"W Yang","year":"2024","unstructured":"Yang, W. et al. Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus. J. Antimicrob. Chemother. 79, 3132\u20133141. https:\/\/doi.org\/10.1093\/jac\/dkae331 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"29583_CR66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/cbic.201600622","volume":"18","author":"Y Abouelhassan","year":"2017","unstructured":"Abouelhassan, Y., Basak, A., Yousaf, H. & Huigens, R. W. 3rd. Identification of N-Arylated NH125 analogues as rapid eradicating agents against MRSA persister cells and potent biofilm killers of Gram-Positive pathogens. Chembiochem 18, 352\u2013357. https:\/\/doi.org\/10.1002\/cbic.201600622 (2017).","journal-title":"Chembiochem"},{"key":"29583_CR67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s42770-022-00696-3","volume":"53","author":"D Misra","year":"2022","unstructured":"Misra, D. et al. Anti-enteric efficacy and mode of action of tridecanoic acid Methyl ester isolated from monochoria hastata (L.) Solms leaf. Braz J. Microbiol. 53, 715\u2013726. https:\/\/doi.org\/10.1007\/s42770-022-00696-3 (2022).","journal-title":"Braz J. Microbiol."},{"key":"29583_CR68","doi-asserted-by":"publisher","first-page":"579806","DOI":"10.3389\/fmicb.2021.579806","volume":"12","author":"P She","year":"2021","unstructured":"She, P. et al. Drug repurposing: in vitro and in vivo antimicrobial and antibiofilm effects of bithionol against Enterococcus faecalis and Enterococcus faecium. Front. Microbiol. 12, 579806. https:\/\/doi.org\/10.3389\/fmicb.2021.579806 (2021).","journal-title":"Front. Microbiol."},{"key":"29583_CR69","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41467-022-29493-0","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium. Nat. Commun. 13, 1888. https:\/\/doi.org\/10.1038\/s41467-022-29493-0 (2022).","journal-title":"Nat. Commun."},{"key":"29583_CR70","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky, J. A., Steenbergen, J. & Zhanel, G. G. Microbiology and preclinical review of Omadacycline. Clin. Infect. Dis. 69, S6\u2013s15. https:\/\/doi.org\/10.1093\/cid\/ciz395 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"29583_CR71","doi-asserted-by":"publisher","first-page":"17938","DOI":"10.1038\/s41598-019-54212-z","volume":"9","author":"M Berditsch","year":"2019","unstructured":"Berditsch, M. et al. Supreme activity of Gramicidin S against resistant, persistent and biofilm cells of Staphylococci and enterococci. Sci. Rep. 9, 17938. https:\/\/doi.org\/10.1038\/s41598-019-54212-z (2019).","journal-title":"Sci. Rep."},{"key":"29583_CR72","doi-asserted-by":"publisher","unstructured":"Lagatolla, C., Mehat, J. W., Ragione, L., Luzzati, R. M., Di Bella, S. & R. & Vitro and in vivo studies of Oritavancin and fosfomycin synergism against Vancomycin-Resistant Enterococcus faecium. Antibiot. (Basel). 11. https:\/\/doi.org\/10.3390\/antibiotics11101334 (2022).","DOI":"10.3390\/antibiotics11101334"},{"key":"29583_CR73","doi-asserted-by":"publisher","first-page":"767e761","DOI":"10.1016\/j.cmi.2015.05.025","volume":"21","author":"A Dalhoff","year":"2015","unstructured":"Dalhoff, A. et al. Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle. Clin. Microbiol. Infect. 21, 767e761\u2013767e764. https:\/\/doi.org\/10.1016\/j.cmi.2015.05.025 (2015).","journal-title":"Clin. Microbiol. Infect."},{"key":"29583_CR74","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1128\/aem.01790-09","volume":"76","author":"J Wang","year":"2010","unstructured":"Wang, J. et al. Identification and analysis of the biosynthetic gene cluster encoding the thiopeptide antibiotic cyclothiazomycin in streptomyces hygroscopicus 10\u201322. Appl. Environ. Microbiol. 76, 2335\u20132344. https:\/\/doi.org\/10.1128\/aem.01790-09 (2010).","journal-title":"Appl. Environ. Microbiol."},{"key":"29583_CR75","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1128\/aac.02590-15","volume":"60","author":"A Deshpande","year":"2016","unstructured":"Deshpande, A. et al. Effect of Fidaxomicin versus Vancomycin on susceptibility to intestinal colonization with Vancomycin-Resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob. Agents Chemother. 60, 3988\u20133993. https:\/\/doi.org\/10.1128\/aac.02590-15 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29583_CR76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jhin.2018.10.023","volume":"101","author":"S Messler","year":"2019","unstructured":"Messler, S. et al. Reduction of nosocomial bloodstream infections and nosocomial vancomycin-resistant Enterococcus faecium on an intensive care unit after introduction of antiseptic octenidine-based bathing. J. Hosp. Infect. 101, 264\u2013271. https:\/\/doi.org\/10.1016\/j.jhin.2018.10.023 (2019).","journal-title":"J. Hosp. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29583-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:10:45Z","timestamp":1767622245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29583-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["29583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29583-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}